Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Neuroimaging in MDD
NCT03609190Phase 1Completed
- Sponsor
- Psychiatrische Universitätsklinik Zürich
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Psychiatrische Universitätsklinik Zürich. Primary endpoints: Change in functional reactivity to emotional stimuli at 24 hours, Change in glutamate concentrations in prefrontal cortex at 24 hours and 1 more. Started Jan 2015; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03609190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609190.